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Objective    Although metastasis of hepatocellular carcinoma to the brain is uncommon, it is as-
sociated with a very high mortality rate and most patients usually expire within 1 year after brain metas-
tasis. The aim of this study is to identify the effectiveness of the active interventions such as gamma knife 
radiosurgery or surgical intervention for these patients.
Methods    We retrospectively reviewed the medical records and imaging data of 59 patients with 
metastatic brain tumors from hepatocellular carcinoma from May 2004 to September 2012. The study 
included patients with available clinical and radiological data who had been diagnosed with metastatic 
hepatocellular carcinoma of the brain, confirmed by magnetic resonance imaging. The overall survival time 
was analyzed and compared according to each risk factor.
Results    The mean age at diagnosis of metastatic brain tumor was 52.2 years (14-77). The 
mean follow-up duration was 13.3 weeks (0.1-117.6). Overall median survival was 4.3 weeks (95% con-
fidence interval, 2.2-6.4). The results from an analysis of clinical factors related to survival revealed that 
treatment modalities were significantly related to the patient’s survival (log rank, p=0.006). Twenty pa-
tients (32.8%) experienced tumor bleeding, and the survival time of the patients with tumor bleeding 
tended to be shorter, although the result was not statistically significant (log rank, p=0.058). Hepatic re-
serve, by Child-Pugh classification, was grade A in 38 patients (64.4%), grade B in 16 patients (27.1%), 
and grade C in 5 patients (8.5%), and was significantly related to the patient’s survival (log rank, 
p=0.000).
Conclusion    Although patients with metastatic brain tumors from hepatocellular carcinoma 
showed poor survival, active intervention including surgical resection or gamma knife radiosurgery may 
result in better survival, especially if patients have preserved liver function.
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INTRODUCTION
Hepatocellular carcinoma (HCC) represents one of the 
most common causes of cancer related deaths world-wide [1]. 
The incidence of HCC demonstrates a striking geographic 
variability, with the highest rates in East and South-East Asia 
and Sub-Saharan Africa [1]. As Korea is an area of endemic 
Hepatitis B Virus, HCC is the third most common cancer 
and the third leading cause of cancer deaths in Korea.
Brain metastasis is the most common intracranial neopl-
asm in adults and is associated with significant morbidity and 
mortality. Considerable research has focused on improving 
both survival and quality of life for these patients. However, 
brain metastasis from HCC is extremely rare, with a reported 
frequency ranging from 0.2% to 2.2% [2-6]. Though uncom-
mon, it is associated with a very high mortality rate and most 
patients die within 1 year [7-10].
The identification of prognostic factors and optimal treat-
ment strategies are still being researched. We analyzed the 
treatment results of metastatic brain tumors from HCC, and 
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compared the prognosis according to the treatment modality.
MATERIALS AND METHODS
From May 2004 to September 2012, a total of 182 patients 
were diagnosed with brain metastasis from HCC at our hos-
pital. We retrospectively reviewed the clinical and imaging 
data. The medical records of these patients were reviewed and 
data collected regarding patient characteristics, clinical pre-
sentation, treatment, and clinical course. In all patients, brain 
metastases were diagnosed by computed tomography (CT) 
scans and magnetic resonance imaging (MRI). The study in-
cluded patients with available clinical and radiological data 
who had been diagnosed with metastatic hepatocellular carci-
noma of the brain, confirmed by MRI. A total of 59 patients 
met the inclusion critera and were enrolled. Overall survival 
time after diagnosis of brain metastasis was analyzed and com-
pared according to risk factors such as gender, presenting sym-
ptoms, presence of tumor bleeding, and treatment modalities.
Treatment modalities for brain metastasis from HCC were 
surgical resection, gamma knife radiosurgery (GKS), whole 
brain radiation therapy (WBRT), and best supportive care 
(BSC). Based on T1 weighted images with gadolinium en-
hancement and T2 weighted images, GKS was performed us-
ing Leksell Gamma Knife type C or Perfexion (Elekta Instru-
ment AB, Stockholm, Sweden). Mean GKS dosage was 15.3 
Gy (range 14.5-20) at marginal dose. WBRT dosage range was 
30 Gy to 45 Gy with 10 to 15 fractions. Supportive care includ-
ed intravenous injections of steroid and hyperosmolar solu-
tions.
Overall survival time and factors affecting survival time 
were analyzed. These were estimated according to the Kaplan-
Meier method and measured from the date of diagnosis of 
brain metastasis until the date of last follow-up or until death. 
Survival curves were compared using the log-rank test, with 
p<0.05 considered statistically significant. Statistical analyses 
were performed using SPSS software version 13.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Characteristics of patients
Patients’ mean age at diagnosis of brain metastasis was 52.2 
years (range 14-44). Mean follow-up duration was 13.4 weeks 
(0.1-117.6). Among 59 patients, 49 patients (83%) were male, 
10 patients (17%) were female. Among 59 patients, hepatic 
reserve, by Child-Pugh classification, was grade A in 38 pa-
tients (64.4%), grade B in 16 patients (27.1%), and grade C in 
5 patients (8.5%). Twenty patients (33.9%) experienced tumor 
bleeding. There were four types of initial treatment modality 
performed in our patients. Seventeen patients (28.8%) receiv-
ed supportive care. Twenty patients (33.9%) were treated with 
GKS, 14 patients (23.7%) were treated with surgical resection, 
and 8 patients (13.6%) were treated with WBRT. Fifty-one 
patients (86.4%) had symptoms such as motor weakness and 
mental status change. Fifty-five patients (93.2%) had other 
extracranial metastasis and 4 patients (6.7%) had no other ex-
tracranial metastasis. Among 59 patients, recursive partition-
ing analysis (RPA) classification was class A in 1 patient (1.6%), 
class B in 16 patients (59.3%), and class C in 5 patients (38.9%). 
Clinical characteristics of the patients are summarized in Ta-
ble 1. There was no statistically significant difference among 
patients group by initial treatment modality (Table 2).
Overall survival time and prognostic factors
Median overall survival after diagnosis of brain metastases 
was 4.3 weeks (95% confidence interval 2.2-6.3 weeks) (Fig. 
1). Overall survival was analyzed according to patient charac-
Table 1. Clinical characteristics of patients
Characteristic No. of patients (%)
Age at diagnosis of brain metastasis;
  median (year, range)
      52.2 (14-77)
Gender
Male    49 (83)
Female    10 (17)
Child-Pugh’s classification
A        38 (64.4)
B        16 (27.1)
C        5 (8.5)
Tumor bleeding
Yes        20 (33.9)
No        39 (66.1)
Initial treatment modality
BSC        17 (28.8)
GKS        20 (33.9)
Surgical resection        14 (23.7)
WBRT           8 (13.6)
Neurological symptoms*
Symptomatic        51 (86.4)
Asymptomatic           8 (13.6)
Other extracranial metastasis
Yes        55 (93.2)
No        4 (6.7)
RPA class
A        1 (1.6)
B        35 (59.3)
C        23 (38.9)
*Including headache, decreased mental status, weakness and so on. 
BSC: best supportive care, GKS: gamma knife radiosurgery, WBRT: 
whole brain radiation therapy, RPA: recursive partitioning analysis
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teristics (Table 3). The median survival varied by initial treat-
ment modality. Median survival was for patients treated with 
WBRT was 4.3 weeks, and the median survival for patients 
treated with GKS was 5.3 weeks. Patients receiving surgical 
resection had a median survival of 14.7 weeks, and those re-
ceiving supportive care had a median survival of 1.9 weeks. 
These results reveal that initial treatment modalities impacted 
the patient’s survival (log rank, p=0.006) (Fig. 2). After surgi-
cal resection, all patients were planned to undergo tumor 
bed GKS or WBRT as adjuvant treatment. However, only 11 
patients were completed adjuvant treatment and the remain-
ing 3 patients did not complete the treatment course because 
of poor neurological or systemic condition for receiving adju-
vant treatment. Median survival of patients without tumor 
bleeding was 4.6 weeks and that of patients with tumor bleed-
ing was 3.9 weeks. Tumor bleeding was correlated with poor 
outcomes, although the presence of tumor bleeding had no 
statistically significant difference (log rank, p=0.08).
Median survival of patients without neurological symptom 
was 4.1 weeks, while that of patients with neurological symp-
toms was 4.3 weeks. The presence of neurological symptoms 
was not statistically significant (log rank, p=0.514). With re-
spect to hepatic reserve, by Child Pugh’s classification, median 
survival was 9.3 weeks for Grade A patients, 3.3 weeks for 
Grade B patients and 0.7 weeks for Grade C patients (Fig. 3). 
There was a significant survival difference between Grade A 
or B patient groups compared to the Grade C patient groups 
(log rank, p=0.00).
With respect to RPA classification, the median survival was 
Table 2. Clinical characteristics of patients by initial treatment modality
Initial treatment modality Surgical resection GKS WBRT BSC Total p value
Age at diagnosis of brain metastasis;  
  median (year, range)
50 (35-66) 51.3 (14-77) 58.3 (47-66) 52.2 (27-71) 0.431
Gender 0.859
Male 12 17 7 13 49
Female 2 3 1 4 10
Child-Pugh’s classification 0.094
A 10 16 5 7 38
B 4 3 3 6 16
C 0 1 0 4 5
Tumor bleeding 0.759
Yes 5 5 3 7 20
No 9 15 5 10 39
Neurological symptoms* 0.540
Symptomatic 14 18 7 13 52
Asymptomatic 0 2 1 4 7
Other extracranial metastasis 0.817
Yes 13 18 8 16 55
No 1 2 0 1 4
RPA class 0.008
I 1 0 0 0 1
II 9 16 6 4 35
III 4 4 2 13 23
*Including headache, decreased mental status, weakness and so on. BSC: best supportive care, GKS: gamma knife radiosurgery, WBRT: whole 
brain radiation therapy, RPA: recursive partitioning analysis
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Fig. 1. Overall survival.
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2.3 weeks for Grade A patients, 9.3 weeks for Grade B patients 
and 2.6 weeks for Grade C patients. There was a significant 
survival difference according to RPA classification (log rank, 
p=0.001).
Results using Cox’s proportional hazards model were de-
scribed in Table 4. Child-Pugh’s classification was statistically 
significant (p=0.000) and the odds ratio was 3.325. Initial 
treatment modality was statistically significant (p=0.009) and 
the odds ratio was 1.526. The odds ratio of RPA classification 
was 1.826, although there was no statistical significance (p= 
0.108). The other factors were not statistically significant.
DISCUSSION
In the past, HCC was often diagnosed at an advanced stage, 
and therefore had a very poor prognosis [11]. However, recen-
tly, close surveillance with advanced diagnostic modalities on 
high-risk patients has facilitated the detection of HCC at a 
much earlier stage. Together with considerable advances in 
treatment for HCC, such as surgical resection, percutaneous 
ablation, transcatheter arterial chemoembolization, and liver 
Table 3. Overall survival time according to patient’s characteris-
tics
Variable n
Median survival 
time in weeks 
(95% CI)
p value
Initial treatment modality 0.006
BSC 17 1.9 (1.34-2.46)
GKS 20   5.3 (0.00-11.65)
Surgical resection 14 14.7 (5.59-23.80)
WBRT 8 4.3 (1.84-6.76)
Tumor bleeding 0.08
Yes 20 3.9 (0.05-7.74)
No 39   4.6 (0.00-13.31)
Neurological symptom 0.514
Yes 51 4.3 (1.36-7.23)
No 8 4.1 (0.00-8.25)
Child-Pugh’s classification 0.000
A 38   9.3 (3.10-15.49)
B 16 3.3 (1.82-4.77)
C 5 0.7 (0.05-1.34)
RPA class 0.001
A 1 2.3
B 35      9.3 (0.533-18.07)
C 23      2.6 (1.558-3.642)
CI: confidence interval, BSC: best supportive care, GKS: gamma 
knife radiosurgery, WBRT: whole brain radiation therapy
Table 4. p value and hazard ratio using Cox’s proportional haz-
ards model
Variable p value Odds ratio 95% CI
Gender 0.789 0.884 0.360-2.176
Child-Pugh’s classification 0.000 3.325 1.864-5.931
Tumor bleeding 0.542 0.797 0.385-1.650
Neurological symptoms* 0.340 0.601 0.211-1.711
Initial treatment modality 0.009 1.526 1.113-2.092
Other extracranial  
  metastasis 
0.899 0.923 0.269-3.172
RPA class 0.108 1.826 0.876-3.805
*Including headache, decreased mental status, weakness and so on. 
CI: confidence interval, RPA: recursive partitioning analysis
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Fig. 2. Median survival by initial treatment modality (log-rank, p= 
0.006). BSC: best supportive care, GKS: gamma knife radiosur-
gery, WBRT: whole brain radiation therapy.
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Fig. 3. Median survival by Child-Pugh’s classification (log-rank, p= 
0.000).
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transplantation, the survival of HCC patients has improved 
considerably in recent years [12-16].
With survival time increasing due to controlled intrahepat-
ic recurrence, the reported incidence of extra-hepatic metas-
tasis in patients with HCC patients is gradually increasing 
[6,17]. Choi et al. [2] reported when HCC does produce ex-
tra-hepatic metastasis, the most common site for spread is the 
lung (34-70%), with additional metastatic sites including re-
gional lymph nodes (16-45%), bone (6%), adrenal glands, and 
occasionally the peritoneum, pancreas, or kidney.
There are some reports on the incidence of brain metastasis 
from HCC. Brain parenchymal metastasis is relatively uncom-
mon, even in Asian patients. However, with survival time in-
creasing, several reports pertaining to brain metastasis from 
HCC were published, although the reported incidence varies 
from 0.2% to 2.2% in the literature [1,4,5]. Some studies attri-
bute the infrequency of brain metastasis from HCC to low af-
finity between HCC cells and the brain [5,9,10,18,19].
Although brain metastasis from HCC is rare, the incidence 
of brain metastasis from HCC may be underestimated. One 
reason may be hepatic encephalopathy, an important finding 
in late-stage HCC patients that can mask neurological presen-
tations of patients with brain metastasis from HCC [9,10,20]. 
Moreover, brain imaging studies are not routinely examined 
in most institutes. Accordingly, brain metastasis in asymp-
tomatic patients would go undetected until they cause neuro-
logical symptoms [21]. For estimating the exact incidence, 
and proper diagnosis with treatment, active consideration of 
neuroimaging studies such as CT or MRI in HCC patients is 
recommended. This may improve patient’s prognosis by early 
detection and intervention for brain metastasis from HCC.
Brain metastasis from HCC is frequently associated with 
tumor bleeding, because HCC is hypervascular and most pa-
tients have coagulopathy due to decreased liver function [22]. 
A
C
B
D
Fig. 4. A: Preoperative MRI revealed a metastatic brain tumor at right frontal lobe with tumor bleeding. B: Preoperative CT revealed a metastatic 
brain tumor at right frontal lobe with tumor bleeding. C: Postoperative MRI revealed that the tumor was removed. D: Follow-up MRI (two months 
after operation) revealed that the tumor had recurred along the resection margin. After that, further gamma knife radiosurgery was done.
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Jiang et al. [21] reported 46.3% of patients (19/41) with brain 
metastasis from HCC experienced tumor bleeding. In our 
study, 33.9% of patients (20/59) presented with hemorrhagic 
brain metastases. Our results showed that patients who expe-
rienced tumor bleeding had poorer outcomes (3.9 vs. 4.6 
week survival time, log rank p=0.08), though the result was 
not statistically significant. Although these results may be 
caused by more severe neurological dysfunction due to in-
creased intracranial pressure, with adequate surgical interven-
tion, patient survival improved. 
Current study results are consistent with previous reports 
that the 1-year survival rate is approximately 40% for patients 
with brain metastasis of HCC. In our study, the median over-
all survival was 4.3 weeks (95% confident interval, 2.2-6.4) 
and the prognosis of patients with brain metastasis from 
HCC was poor.
Our study results revealed statistically significant differenc-
es according to initial treatment modality. Median survival 
time of patients who underwent surgical resection and GKS 
was statistically longer than for those receiving supportive 
care and WBRT (surgical resection group, 14.7; GKS group, 
5.3 weeks; WBRT group, 4.3 weeks; BSC group, 1.9 weeks). 
Choi et al. [2] also reported patient groups treated with surgi-
cal resection or GKS showed better survival compared to the 
patient groups treated with BSC or WBRT. Chang et al. [9] 
found that patients with brain metastasis from HCC who un-
derwent surgery and/or radiation therapy had a survival time 
of more than 4 months, while those who received only sup-
portive care died within 1 month. The prognosis with sup-
portive care is poor due to spread of HCC to multiple organs 
and repeated intracranial hemorrhage [9,23].
Also, there was a statistically significant difference based on 
hepatic reserve by Child-Pugh’s classification. While the me-
dian survival of Child-Pugh’s classification of Grade A pa-
tients was 9.3 weeks, that of Grade C patients was only 0.7 
weeks. A number of authors have reported the importance of 
the Child-Pugh’s classification score as a prognostic indicator. 
Considering that almost all patients with HCC have decreased 
liver function and that hepatic failure is a major cause of death, 
liver function may be a factor in the overall survival after treat-
ment in patients with HCC [2]. Another factor affecting the 
survival of patients was RPA classification. RPA classification 
is well known prognostic factor for metastatic brain tumors 
[24]. In our study, RPA classification was one of the signifi-
cant prognostic factors, which was similar to previous studies. 
Based on these results, for patients with Child-Pugh’s clas-
sification Grade A or B, RPA classification, and active treat-
ments such as surgical resection or GKS seem more appro-
priate than conservative treatments such as WBRT or suppor-
tive care.
Contrary to our expectations, there was no statistically sig-
nificant difference based on the presence of neurological sym-
ptoms (log rank, p=0.514). In general, the prognosis for pa-
tients with brain metastasis depended on the number of me-
tastases and the Karnofsky performance status scale (KPS) 
score [25]. In our study, the presence of neurological symp-
toms, generally a a factor on KPS score, was not prognostic 
(log rank, p=0.514). This may be due to the very short sur-
vival time of patients with brain metastasis from HCC. Fur-
ther study is needed to investigate this.
Using Cox’s proportional hazards model, factors affecting 
survival time of metastatic brain tumor from HCC was anal-
ysed and p value and odds ratio was calculated. Child-Pugh’s 
classification and initial treatment modality was significant 
A CB
Fig. 5. A: Pre-GKS MRI revealed a metastatic brain tumor at the left occipital lobe. B: Follow-up MRI (three months after GKS) shows a de-
crease in the extent of the enhancing portion of the mass. C: Follow-up MRI (six month after GKS) shows no evidence of tumor recurrence. GKS: 
gamma knife radiosurgery.
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factors affecting survival time and such odds ratio were de-
scribed in Table 4.
This study found that active treatments such as surgical re-
section or GKS may increase the survival time of selected pa-
tients with brain metastasis from HCC. Favorable prognostic 
factors were Child-Pugh’s classification Grade A or B. Further 
study regarding detail indications for active treatment seems 
to give longer survival time for the patients with brain metas-
tasis from HCC.
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